In this week’s blog, guest author Ahmed Albaiti (Principal, ZS), makes a case for why the recent wave of bad news in digital health may just be the focused push that the industry needs.

In the recent years, patient engagement has gained great popularity in healthcare. The most impactful and adoptable solutions come from involving patient experts, key opinion leaders and other key stakeholders in a collaborative 'co-creation' process.

Our HealthXL meetings in April covered everything from ‘Data Monetisation for MedTech Companies’ to ‘The Potential of OTC DTx Solutions’. To make sure you’re not missing out on the top insights from our communities, and get a sneak peak at some of the conversations, here are my top five takeaways.

DTx solutions have been developed, theoretically, to remove many of the barriers associated with traditional care models and be more scalable and readily available. However, these solutions are not always accessible or inclusive for the populations that could benefit from them the most.

Pharma-DTx partnerships can be a good strategy when both the pharma and the DTx companies speak the same language. While successful pilots have been demonstrated, there are challenges in scaling and sustaining innovations that generate value and return on investment (ROI) for pharma companies.

Our HealthXL meetings in March covered everything from ‘Navigating the DiGA Framework’ to ‘Leveraging Sources of US Government Funding for Digital Health’. Make sure you’re not missing out on the topics that matter the most to our communities and are plugged into the conversation.

Over the past decade, pharma’s interaction with digital health has grown more sophisticated and purposeful. In the last year however, innovation wrapped around the drug has become the object of budgetary scrutiny in pharmaceutical companies. So why continue to invest in digital health?

In this blog we analyse the current landscape of RNA therapeutics and postulate on where best digital health may support this innovative area of medicine.

While the healthtech sector has evolved significantly in the past few years, 2023 looks set to be another year of significant change. At our Global Gathering in Munich, startups, pharma, and investors split up into several roundtables, tackling the several topics. Here is what we learned.

Pear Therapeutics announced last week that they are looking into “strategic alternatives” that could bolster its current precarious financial situation. Pear has been on the public markets since late 2021, however, its stock price has declined over the last two years.

FDIC's decision to close SVB has had an immediate impact on startup and tech companies, including those in digital health. With rising interest rates, investors have become increasingly conservative with their investments, focusing on a more targeted investment strategy.

Mental health has been a pioneering area for digital therapeutics and a keen area of focus for digital health in recent years. As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028.

There was a wide range of topics discussed at our HealthXL meetings this February. To make sure you’re not missing out on the insightful discussions between community members and to keep you plugged into the conversation, here are Tess' five meeting takeaways from the past month.

A key component to ensuring the adoption of digital health products is market access and reimbursement. In this week’s blog, we explore France's new fast-track reimbursement pathway for digital health and how it compares to Germany's DiGA pathway.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint, we discussed the pharma sales models for DTx-drug combination products. In this blog, we’ve pulled out the top takeaways from this series.

Over the past month, our HealthXL community members have discussed the opportunities for digital health in retail healthcare, using real-world data (RWD) to increase market access and revenue generation in DTx partnerships among other topics. Here's a snapshot of expert insights from these meetings.

In part two, Jeremy Sohn, Managing Partner at P74 Ventures, continues to explore why the wave of innovation in pharma happened too quickly and the primary forces driving the need for change.

In this blog, Jeremy Sohn, Managing Partner at P74 Ventures, explores the complexity of innovation in the pharmaceutical industry, why it sometimes experiences friction, and what factors have contributed to pharma embracing innovation.

This week we look back at some of the biggest news stories from January. Read about Google and DeepMind's MedPaLM, reflections on the Consumer Electronics Show, and more.

After a booming few years of growth in digital health, things returned to a normal cadence in 2022. Yet not all was quiet either: the femtech market continued to grow and Europe launched its first-ever digital health action plan. In this blog, we recap the most notable developments in 2022.

We’re back with part two of our three-part blog series on Digital Health 3.0. This week, Robert Garber, Partner at 7wireVentures, explores challenges within healthcare, barriers to technology adoption, and how digital health might just be the fix we need. 

2022 has been a jam-packed year at HealthXL full of in-person events, advisory reports and new product features. Thanks to our amazing community members and advisory team, we expect 2023 to be even more informative and eventful. In this blog, we recap on our top six highlights for the year.

To kick things off this January, we are bringing you a three part blog series focused on the next phase of digital health - Digital Health 3.0 - authored by leading industry experts who succinctly explore how we’ve landed at this crossroads and hypothesize on what’s next for digital health.

Over the past month, our HealthXL community members discussed new distribution channels for DTx, seeking capital for DTx products and digital health pharma partnerships, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

In our Friday newsletter we recap the biggest news story of the week to make sure you don’t miss out on the latest trends, developments, and acquisitions in digital health. In case you missed it (ICYMI), this round-up will catch you up on the top stories from the past month.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed “How to Overcome the Blockers to DTx Adoption and Measure Success.” In this blog we’ve pulled out the top takeaways from this series.

A recent report on global augmented and virtual reality in healthcare showed the market is projected to reach around $19.6 billion by 2030 from 2.3 billion in 2021. With this massive growth, there are high expectations for augmented reality (AR) and virtual reality (VR) technologies.

Over the past month, our HealthXL community members discussed getting virtual care solutions into physicians and care teams workflows, scalable business models for oncology digital health solutions, and the cost of digital health solutions, among other topics.

In our Friday newsletter, we recap the biggest news story of the week so you don’t miss out on the latest trends, developments, and acquisitions in digital health. In case you missed it (ICYMI), this round-up will catch you up on the top stories from the past month.

In our most recent sprint we discussed DTx and pharma partnerships in mental health. In this blog we’ve pulled out the top takeaways from this series.

Individuals are becoming more engaged in their healthcare decision making and the ownership of their personal health information. There’s a demand for faster and more accessible alternatives to inconvenient and time consuming in-person lab tests. Is Diagnostics-as-a-Service (DaaS) the answer?

Over the past month, our HealthXL community members discussed digital health evidence requirements, DTx label claims, and DTx - pharma collaborations, among other topics

In our Friday newsletter, we recap the biggest news story of the week so you don’t miss out on the latest trends, developments, and acquisitions in digital health.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed HCP and patient adoption of virtual care in oncology. In this blog we’ve pulled out the top takeaways from this series.

“In the metaverse, you’ll be able to do almost anything you can imagine,” Mark Zuckerberg, the chief executive of Meta, said late last year. So how is the digital health industry tapping into the metaverse?

Over the past month, our HealthXL community members discussed the value of DTx-generated RWD, DTx Reimbursement in the US-Value- Based Contracting (VBC) Basics, and Remote Patient Monitoring programs for Pharma, among other topics.

In our Friday newsletter, we recap the biggest news story of the week so you don’t miss out on the latest trends, developments, and acquisitions in digital health. In case you missed it (ICYMI), this round-up will catch you up on the top stories from the past month.

In this blog we explore some of the trends predicted to drive and challenge the growth in the digital biomarker market over the projected period. 

Over the past month, our HealthXL community members discussed the adoption of prescription digital therapeutics (DTx), routes to market for digital health in oncology, and approaching investors with DTx, among other topics.

In this blog we explore the current state of the DiGA and the potentially changing view of DiGA as a stand-out model as compared to other reimbursement pathways.

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges

In April, HealthXL community members discussed evidence generation strategies for digital therapeutics (DTx), clinical and economic evidence for standalone DTx and non-prescription DTx (non-PDT) patient engagement, among other topics. Here's a snapshot of five expert insights from these meetings.

In our two-part HealthXL Sprint meetings, we connect senior leaders across our community to solve health challenges.

Over the past month, our HealthXL community members met to discuss topics ranging from evidence gathering for Digital Therapeutics (DTx), to reimbursement in the US, Software as a Medical Device (SaMD) regulation in the EU among others.

Building a digital health ecosystem - The key takeaways from our global gathering in Basel

Digital tools are beginning to have a real impact on cancer patient outcomes. Now is the time to come together as a community to accelerate innovation.

This past month, 109 of our HealthXL community members met across 12 meetings to discuss digital measures in clinical trials, clinical and economic outcomes for RMP, and DTx last mile delivery, among other topics. We’ve put together a snapshot of 5 expert insights from these meetings.

Every Friday we recap the biggest news story of the week to make sure you don’t miss out on the latest trends, developments, moves and acquisitions in digital health.

The digital therapeutic (DTx) landscape is rapidly evolving with DTx securing a record-breaking $3.4B across 122 investments in 2021

While the healthcare industry is buzzing with increased digital health market activity, Digital Therapeutics (DTx) companies have started to pique Pharma’s interest.

A Round-up of 5 Expert Insights from the HealthXL Community

Every Friday we recap the biggest news story of the week to make sure you don’t miss out on the latest trends, developments, moves and acquisitions in digital health.

In this blog post we explore 5 questions from the report. HealthXL Community members can access the full report from our platform. Not a member yet? You can download an exclusive free snapshot of Part II here. 

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges.

This was a booming year of growth in the world of digital health, with first of their kind investments, acquisitions and product launches. We’ve captured the top 10 things we saw and did in our 2021 year in review.

Every Friday we recap the biggest news story of the week to make sure you don’t miss out on the latest trends, developments, moves and acquisitions in digital health. But in case you missed it (ICYMI) this round-up will catch you up on the top stories from the past month.

This past month, 124 of our HealthXL community members met across 13 meetings to discuss HCP and patient adoption, commercialisation models for virtual care in respiratory disease, and Germany’s DiGA pathway, among other topics.

This blog is the output from HealthXLs’ meeting series that explored DTx in the Mental Health space.

The Status Quo: Women’s health tech solutions have mostly been period or fertility trackers.

At the end of October it felt like some normality had returned to Dublin as innovators and global leaders in the digital health space arrived to take part in our first in-person event in Ireland since the onset of the pandemic. We gathered in The Mansion House to discuss all things DTx.

This blog is the output from HealthXLs’ meeting series that explored the commercialisation models for Prescription DTx as well as its adoption and the last-mile delivery challenges.

This blog is an output from a Chief Digital Officer (CDO) Roundtable Discussion hosted by HealthXL and BrightInsight on the top 5 challenges and solutions to adopting digital health in biopharma. 

While many industries struggled to hold their ground in the midst of the COVID-19 pandemic, the healthcare industry thrived. In fact, the pandemic fuelled the transition towards telemedicine

Our meetings create a space for industry experts to connect and discuss the most current and evolving topics in the digital health space.

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar.

In this article we’ll explore some of the opportunities for medtech and digital companies to partner across the medtech product lifecycle in order to support longitudinal care.

The COVID-19 pandemic has devastated the world and has left significant lasting consequences on many sectors, particularly the clinical research and clinical trials industry. Clinical trials are an essential component of the drug approval process and provide vital information about a drug's safety.

Our meetings create a space for industry experts to connect and discuss the most current and evolving topics in the digital health space. This segment highlights key learnings and ideas cultivated by our network of payers, providers, pharmaceutical companies, health care and technology organizations

HealthXL and a consortium of representative stakeholders from across the digital health ecosystem are working to advance the understanding and adoption of digital health products used in clinical trials.

In a recent HealthXL meeting series we explored the current DTx solutions in Neurology, unmet needs and the different commercial and adoption strategies for the companies operating in the area. Read our latest blog to find out the key insights form the meeting series.

The prevalence of mental health conditions had been relatively stable before 2020, however, this trend changed at the onset of the COVID-19 pandemic. Globally, the mental health of the population deteriorated.

In this blog, we look at the intersection of digital health and health policy. Worldwide eHealth policy stems from recommendations from the WHO’s ‘Global Strategy on Digital Health 2020-2025’ which is being implemented in more than 120 Member States, including low and middle-income countries

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar.

HealthXLs digital health meetings bring the leaders in digital health together. We have run 8 interactive masterclasses so far this year, where key experts from the HealthXL community have shared their expertise in trending areas of digital health.

Despite women making up just under 50% ( 49.6%) of the global population, women’s healthcare has been characterised as under-funded and insufficient, with women’s health accounting for only 4% of the overall funding in research and development for healthcare products and services.

In this blog we will take a look at the discipline of sociology and, specifically, how the study of society can help us develop more inclusive, equitable, effective and successful digital health solutions and interventions.

The industry is abuzz with activity from teledermatology and dermatology digital health start-ups. While the changing landscape is exciting, it begs the question, are these being used?

With global vaccine roll-outs now well underway and lockdown measures beginning to ease, speculation has begun as to where the “new normal” will settle in the balance between virtual and in-person care. Weighing up the benefits, here we uncover the clinical and financial benefits of RPM.

HealthXL has hosted version 2.0 of its bi-annual Interactive event, bringing together over 120 senior leaders from across the digital health industry to virtually zoom in on some of the biggest challenges facing the industry. Find out what we explored now.

Digital health is an industry destined for IP rivalry. Experts in the industry report that medical device litigation is probably the most contentious with competitor litigations going more frequently to trial than in many other industries. But how is IP protection in digital health achieved?

Telehealth is so much more than seeing your doctor on a screen - it’s not just an evolution of care-delivery, it’s a revolution! In this week's blog we explore some of the big disruptions happening, and some of the opportunities that await.

How exactly are we using healthcare data? And, more importantly, are we using it wisely? Here we explore how we can leverage this massive, and sometimes intimidating resource, to best serve patients and drive innovative outcomes.

As 2021 kicked off with the first-ever virtual J.P. Morgan, HealthXL collaborated with BrightInsight to bring together global leaders from across healthcare, medtech and life sciences to a Digital Health C-Suite meeting series. Here are our key takeaways!

Last year was a year like no other - we saw innovation at accelerating speed across the digital health spectrum. With no sign of things slowing down in 2021, here are our top 5 predictions for trends to keep an eye on in the year ahead.

From the early days of Health Tech to modern Digital Health, Steve is our Videocast guest this month.

Covid-19 presented an opportunity to stress test every assumption, system, and solution in the digital health industry. And it did. Both disruptive and transformative, the crisis has fast-tracked many healthcare trends that were simmering below the surface. Join us for this week's blog as we explore

Has Covid created an opportunity for innovation and startups or the consolidation of innovation by the healthcare giants? Rebecca Love RN, MSN, FIEL, explores in this week's blog.

Join us for our latest podcast as we sit down with Ken Cahill, CEO at SilverCloud Health and Jim Joyce, CEO at HealthBeacon.

Join us for our latest videocast as we catch up with Glen Tullman, Founder/Managing Partner at 7wireVentures, as we discuss technologies impact and adoption in the medical landscape and much more.

Covid-19 has accelerated the adoption of digital health by people all over the world and APAC is no exception. We explore this adoption in this week's blog.

In this videocast, we had the pleasure of speaking with Ritesh Patel, Chief Digital Officer at Ogilvy Consulting. Ritesh discusses how health organisations in the current climate are starting to ‘move the health system from the hospital to the home’.

In our latest videocast, we talk to Steve Kraus, partner at Bessemer Venture Partners.

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines?

Telehealth is one of the rare sectors reaping a net positive effect of Covid-19. They say that “In the midst of every crisis lies a great opportunity” - Could Covid-19 be the opportunity telehealth has been waiting for?

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines?

This is your monthly digest of three noteworthy news stories in digital health from the last few weeks - what they mean for the industry, and why you should know about them.

For anyone in the business of digital health, it is difficult not to pay attention to the patient data debates fought out daily in the news.

In this week's blog we map some of the emerging subsegments of digitally enabled mental health and the evidence and partnerships contributing to the growing maturity of this central tenet of human health and care.

This is your monthly digest of two noteworthy news stories in digital health from the last few weeks - what they mean for the industry, and why you should know about them.